Log in to search using one of your social media accounts:

 

Anti-Diarrheal Medication Recalled Over Potency Concerns
Greenstone has recalled several lots of its diphenoxylate hydrochloride and atropine sulfate tablets because they may be super- or subpotent. If the tablets, which are... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 20, 2017 Category: Primary Care Source Type: news

Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets
For Immediate Release – PEAPACK, NJ, November 16, 2017 - Greenstone LLC, a wholly owned subsidiary of Pfizer Inc., is voluntarily recalling multiple lots of diphenoxylate hydrochloride and atropine sulfate tablets, USP to the consumer level. Greenstone initiated this recall because product from these lots has the pote ntial to be super potent or sub potent. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 16, 2017 Category: Food Science Source Type: news

ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets
BAUDETTE, Minn., June 20, 2017 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Diphenoxylate HCl and Atropine Sulfate Tablets, 2.5mg/0.025mg. The annual U.S. market for... Biopharmaceuticals, Generics, Product Launch ANI Pharmaceuticals, Diphenoxylate, Atropine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 20, 2017 Category: Pharmaceuticals Source Type: news

Lomotil (Diphenoxylate and Atropine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 9, 2017 Category: Drugs & Pharmacology Source Type: news

Summary: International Kidney Cancer Symposium
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found at http://tcga-data.nci.hih.gov/tcga/ FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news